entertainment -WSS

entertainment

author：fashion 2025-08-12 06:44:53 - browse：12287

Hyacinth Empinado/STAT

The body mass index, or BMI, is the formula that’s used most often to diagnose overweight and obesity. But unlike other common diagnoses, there is a certain stigma applied to people with a high body mass index, or BMI, which can affect how they are perceived by peers, providers, and society at large.

Despite the ubiquity of the BMI in medicine, many argue that it is a flawed tool, with a strange history. In recent months, the BMI has become more relevant than ever as the new semaglutide weight loss drugs are poised to change how obesity is understood and treated.

BMI is a simple calculation — a person’s weight in kilograms divided by the square of their height. But how BMI is then translated into a diagnosis is complicated and flawed.

Related: New weight loss drugs are changing the narrative on obesity, with a push from pharma

Watch this video to learn more about the history of the BMI — how it became so entrenched in medicine and, surprisingly, how its introduction may have set back decades of work on how obesity contributes to disease.

A STAT series is examining new obesity drugs that are transforming patients’ lives, dividing medical experts, and spurring one of the biggest business battles in years. Read more about The Obesity Revolution.

Previous article： Supreme Court strikes down use of affirmative action
Next article： NIH nominee Bertagnolli will get October confirmation hearing

explore

WSS

Feng Zhang CRISPR delivery startup lays off quarter of staff

ALS advocates say criticism of new drugs misses bigger picture

New weight loss drugs work. But how can they best be used?

Why Novartis is changing the name of its research labs

A single drug, study failures leave Anavex with nothing but cash

Susan Tousi leaves Illumina to head cancer liquid biopsy startup

Wikipedia

entertainment

Related: New weight loss drugs are changing the narrative on obesity, with a push from pharma

focus

In Memoriam: Notable people who died in 2023

Why psychiatrists like me stop taking insurance

How to save PrEP access — and even expand it

Amazon on where the company's health care bets are headed next

In age of alternative facts, a scholarly course on calling out crap

Insitro, AI biotech unicorn, brings cash, new research to JPM 2024

Drug repurposing or repositioning? The language matters

Videos point to link between seizures and unexplained toddler deaths

Sports medicine is finally prioritizing gender equality

J&J to buy cancer drug developer Ambrx Biopharma

focus

Listen: Biogen's potential pivot, & Illumina's next chapter

How generative AI is inspiring dreams of a health data revolution

Listen: Biogen's potential pivot, & Illumina's next chapter

Readout Newsletter: Allogene's pivot, Illumina exec to lead Delfi

A rare thyroid diagnosis led to unexpected, all

The biotech scorecard for Q1: 17 stock

focus

explore

hotspot

leisure time